Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Prostate Cancer-Derived Urine Exosomes: A Novel Approach To Biomarkers For Prostate Cancer
UroToday.com - In the online edition of the British Journal of Cancer, Dr. J. Nilsson and an international team of investigators report on a new biomarker methodology for prostate cancer (CaP). The authors explain that prostatic secretions contain two types of microvesicles; prostasomes (150-500nm) are produced by prostatic ductal epithelial cells that are a normal component of seminal fluid and participate in male fertility and exosomes which are specialized nanovesicles (30-100nm) with cup-shaped morphology and are actively secreted by normal and tumor cells.
generic viagra online
The Fitness Revolution - Launch Of The UK's First Dedicated Health And Fitness Channel
The fight against obesity has stepped up a gear with the
News of the day
New Bisphenol A Study Is Of Very Limited Relevance To Human Health
The following statement can be attributed to Steven G. Hentges, Ph.D. of the American Chemistry Council"s (ACC) Polycarbonate/BPA Global Group. Dr. Hentges" comments are in regard to a study from researchers at North Carolina State University (NCSU) and the National Institute of Environmental Health Sciences (NIEHS). The study, "Neonatal bisphenol A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin releasing hormone neurons," was funded by NIEHS and published online June 17 by the journal Biology of Reproduction. The study was co-authored by Heather B. Patisaul and Heather B. Adewale of NCSU and Wendy N. Jefferson and Retha R. Newbold of NIEHS.
Oncology

Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received A Conditional IDE Approval For Stellar's Uracyst(R) From The FDA

Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc. ("Watson") (NYSE:WPI), has received a conditional approval of their Investigational Device Exemption (IDE) to conduct clinical work with Uracyst® from The Food and Drug Administration (FDA) in the United States of America ("USA"). This will allow Watson to continue to move their Uracyst® development program forward towards the eventual approval for the sale of Uracyst® in USA. The conditional approval allows Watson to begin a blinded, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the USA. Peter Riehl, Stellar"s President and CEO stated, "We are very pleased to see another important milestone completed by Watson as they continue to make progress towards the sale of Uracyst® in the largest pharmaceutical market in the world. Stellar is fortunate to have a partner as experienced as Watson is in the field of urology to develop the clinical program for the Uracyst marketing approval in the USA." Stellar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009